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Summary
Background Quinine or alternative artemisinin-based combination treatment (ACT) is the recommended rescue 
treatment for uncomplicated malaria. However, patients are often re-treated with the same ACT though it is unclear 
whether this is the most suitable approach. We assessed the eﬃ  cacy and safety of re-treating malaria patients with 
uncomplicated failures with the same ACT used for the primary episode, compared with other rescue treatments.
Methods This was a bicentre, open-label, randomised, three-arm phase 3 trial done in Lisungi health centre in DR 
Congo, and Kazo health centre in Uganda in 2012–14. Children aged 12–60 months with recurrent malaria infection 
after treatment with the ﬁ rst-line ACT were randomly assigned to either re-treatment with the same ﬁ rst-line ACT, an 
alternative ACT,  which were given for 3 days, or quinine-clindamycin (QnC), which was given for 5–7 days, following a 
2:2:1 ratio. Randomisation was done by computer-generated randomisation list in a block design by country. The three 
treatment groups were assumed to have equivalent eﬃ  cacy above 90%. Both the research team and parents or guardians 
were aware of treatment allocation. The primary outcome was the proportion of patients with an adequate clinical and 
parasitological response (ACPR) at day 28, in the per-protocol population. This trial was registered under the numbers 
NCT01374581 in ClinicalTrials.gov and PACTR201203000351114 in the Pan African Clinical Trials Registry.
Findings From May 22, 2012, to Jan 31, 2014, 571 children were included in the trial. 240 children were randomly 
assigned to the re-treatment ACT group, 233 to the alternative ACT group, and 98 to the QnC group. 500 children 
were assessed for the primary outcome. 71 others were not included because they did not complete the follow-up or 
PCR genotyping result was not conclusive. The ACPR response was similar in the three groups: 91·4% (95% CI 
87·5–95·2) for the re-treatment ACT, 91·3% (95% CI 87·4–95·1) for the alternative ACT, and 89·5% (95% CI 
83·0–96·0) for QnC. The estimates for rates of malaria recrudescence in the three treatment groups were similar 
(log-rank test: χ²=0·22, p=0·894). Artemether-lumefantrine was better tolerated than QnC (p=0·0005) and artesunate-
amodiaquine (p<0·0001) in the modiﬁ ed intention-to-treat analysis. No serious adverse events were observed. The 
most common adverse events reported in the re-treatment ACT group were anorexia (31 [13%] of 240 patients), 
asthenia (20 [8%]), coughing (16 [7%]), abnormal behaviour (13 [5%]), and diarrhoea (12 [5%]). Anorexia (13 [6%] of 
233 patients) was the most frequently reported adverse event in the alternative ACT group. The most commonly 
reported adverse events in the QnC group were anorexia (12 [12%] of 98 patients), abnormal behaviour (6 [6%]), 
asthenia (6 [6%]), and pruritus (5 [5%]).
Interpretation Re-treatment with the same ACT shows similar eﬃ  cacy as recommended rescue treatments and could 
be considered for rescue treatment for Plasmodium falciparum malaria. However, the eﬀ ect of this approach on the 
selection of resistant strains should be monitored to ensure that re-treatment with the same ACT does not contribute 
to P falciparum resistance.
Funding Fonds Wetenschappelijk Onderzoek, Vlaamse Interuniversitaire Raad-Universitaire Ontwikkelings 
Samenwerking, European and Developing Countries Clinical Trials Partnership, and the Belgian Technical 
Cooperation-Programme d’Etudes et d’Expertises-in the Democratic Republic of Congo.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Since the early 2000s, a downward trend in the malaria 
burden has been observed, resulting in reductions of 37% 
in malaria incidence and 60% in malaria mortality 
worldwide. Nevertheless, the malaria burden remains 
substantial, with an estimated 214 million cases in 2015, 
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and 438 000 related deaths.1 Within this context, the 
availability of eﬀ ective treatments remains essential for 
sustaining these achievements.
Over a decade ago, WHO recommended artemisinin-
based combination therapies (ACTs) for the treatment of 
uncomplicated malaria, in response to the spread of 
resistance to commonly used antimalarial drugs, namely 
chloroquine and sulfadoxine-pyrimethamine. Combining 
two drugs with diﬀ erent mechanisms of action aimed to 
reduce the emergence of parasitic resistance.2 All 
malaria-endemic countries have adopted ACT as ﬁ rst-
line treatment for uncomplicated malaria. Both DR 
Congo and Uganda have high malaria incidence. A child 
younger than 5 years can have up to ten malaria episodes 
during a year.3,4 Artemether-lumefantrine (AL) is the 
recommended ﬁ rst-line treatment in Uganda, but AL 
and artesunate-amodiaquine (ASAQ) are both recom-
mended in DR Congo, with ASAQ being the most widely 
used. Quinine is recommended for any treatment failure, 
as a rescue treatment.
Quinine has a short half-life, requiring repeated 
dosing over 7 days. Treatment with quinine can lead to 
several adverse events and poor compliance.5–7 Quinine 
can be less eﬀ ective than ACT in patients with 
uncomplicated malaria.5,8 Since most of the treatment 
failures in patients given AL or ASAQ seem to be for 
new infections with low parasite densities,9,10 it might be 
possible to re-treat patients with the same ACT used for 
the primary episode. However, there is little evidence on 
the eﬃ  cacy and safety of recommended rescue 
treatments.11 We therefore aimed to investigate ACT re-
treatment in children who had been treated for 
uncomplicated malaria, and who were experiencing a 
recurrent infection by assessing the eﬃ  cacy and safety 
of re-treatment with the same ACT used for the primary 
episode compared with that of an alternative ACT or 
quinine and clindamycin (QnC).
Methods
Study design
This study was a bi-centre, phase 3b, randomised, open-
label, three-arm trial done at Lisungi Health Center in 
Kinshasa, DR Congo, and Kazo Health Center in 
Mbarara, Uganda. Ethical approval was obtained from 
the Ethics Committee of the School of Public Health at 
the University of Kinshasa (DR Congo), the Uganda 
National Council for Science and Technology (Uganda), 
and the Ethics Committee of the University of Antwerp 
(Belgium). This trial was done in accordance with the 
Good Clinical and Laboratory Practices, applicable 
regulatory requirements, and the Declaration of Helsinki. 
The trial protocol is available online.
Participants
Children aged 12–59 months, weighing at least 9 kg, and 
attending study sites for fever or history of fever were 
given ﬁ rst-line ACT (ASAQ in DR Congo and AL in 
Uganda) and passively followed up (malaria was screened 
only in presence of symptoms) for 42 days (the pre-trial 
phase). The treatment was directly observed by a study 
nurse. The 42-day PCR-adjusted eﬃ  cacy was 93·5% (data 
not shown) for AL in Uganda and 92·8% for ASAQ in DR 
Congo.12 Microscopy was used to diagnose malaria in 
children, who were then assessed for eligibility in the 
randomised trial. To be included in the trial, children had 
to fulﬁ l all the following criteria: recurrent Plasmodium 
falciparum infection with fever or history of fever, 
willingness and ability of the parents or guardians to 
comply with the study protocol for the duration of the 
study, and written informed consent from parents or 
Research in context
Evidence before this study
Artemisinin-based combination therapies (ACTs) are 
recommended for ﬁ rst-line treatment of uncomplicated 
Plasmodium falciparum malaria. If recurrent malaria occurs 
before day 28, WHO recommends an alternative ACT in 
addition to quinine accompanied by an antibiotic having 
antiplasmodial properties (such as clindamycin, tetracycline, or 
doxycycline). This recommendation is based on expert opinion. 
In real-life situations, the prescriber is not always aware of 
former treatments and patients might be re-treated with the 
ﬁ rst-line ACT. We searched in PubMed for randomised trials 
without date or language restrictions, using the MeSH terms 
“uncomplicated malaria”, “retreatment”, “rescue therapy”, or 
“second-line treatment”. We did not identify any trial that had 
investigated the eﬃ  cacy and safety of re-treatment with the 
ﬁ rst-line ACT nor with an alternative ACT. Therefore, we 
undertook this trial to provide evidence. Two malaria-endemic 
countries using diﬀ erent ﬁ rst-line ACTs were selected to host 
the trial (artesunate-amodiaquine in the DR Congo and 
artemether-lumefantrine in Uganda).
Added value of this study
Most ACT treatment failures are reinfections. Our ﬁ ndings show 
that the treatment of recurrent malaria episode with ﬁ rst-line 
recommended ACT has a similar eﬃ  cacy as during the initial 
ﬁ rst-line treatment and as the recommended rescue 
treatments. Furthermore, we provide evidence to conﬁ rm WHO 
experts’ opinion recommending an alternative ACT as rescue 
treatment in addition to quinine.
Implications of all the available evidence
Most primary and community health centres in Africa have only 
one ACT available. The use of the same ACT as a rescue 
treatment might be considered. However, correct dosing 
strategies should be implemented and the eﬀ ect of 
re-treatment on the population genetics of circulating 
P falciparum strains needs to be monitored. 
For the trial protocol see 
http://www.trialsjournal.com/
content/14/1/307
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guardians. Exclusion criteria were: known hypersensitivity 
to or previous serious drug-related adverse events with 
the study drugs, severe malaria or danger signs, treatment 
failure within 14 days after treatment of the primary 
episode; and bodyweight of less than 9 kg. Two written 
informed consents were obtained, the ﬁ rst before 
treatment with the ﬁ rst-line ACT (pre-trial phase) and the 
second before recruitment in the randomised trial.
Randomisation and masking
Patients were randomly assigned to receive either the 
same ACT treatment as the ﬁ rst-line treatment (re-
treatment ACT group), an alternative ACT to the ﬁ rst-
line treatment (alternative ACT group), or QnC (QnC 
group), in a ratio of 2:2:1. In DR Congo, the re-treatment 
ACT group were treated with ASAQ and the alternative 
ACT group were treated with AL, and in Uganda the re-
treatment ACT group were treated with AL and the 
alternative ACT group received ASAQ. Patients assigned 
to the QnC group received the same QnC treatment in 
both countries. Treatment was randomly allocated in 
blocks by country according to a randomisation list that 
was automatically generated by the statistical team at the 
University of Antwerp before starting the study. The 
treatment allocations were sealed in envelopes that were 
opened by the study clinician immediately after obtaining 
the written informed consent. This was an open-label 
study, therefore, investigators and participants (or their 
parents or guardians) were aware of study treatment
Procedures
Children received ASAQ, AL, or QnC and were followed 
up for 28 days. Parents or guardians were asked to return 
to the clinic for follow-up at scheduled visits on days 1, 2, 
3, 7, 14, 21, and 28. They were also encouraged to attend 
the clinic any time the child was unwell.
Study medications were quality assured. AL (Novartis, 
Basel, Switzerland) was administered twice a day, orally 
for three days. Tablets containing 20 mg of artemether 
and 120 mg of lumefantrine were administered with a 
cup of milk (to improve lumefantrine absorption). Dosage 
was according to manufacturer’s instructions: one tablet 
for children weighing 5–14·9 kg, two tablets for children 
weighing 15–24·9 kg, and three tablets for children 
weighing 25–34·9 kg. ASAQ (Sanoﬁ , Casablanca, 
Morocco) was administered once a day, orally for 3 days. 
Tablets contained 50 mg of artesunate and 135 mg of 
amodiaquine for children weighing 9–17·9 kg; 100 mg of 
artesunate and 270 mg of amodiaquine for children 
weighing 18–35·9 kg. Both ACTs were co-formulated. 
Quinine (Sanoﬁ , Gentilly, France) was administered three 
times a day, orally for 7 days. Tablets of 125 mg were 
available. Half a tablet was given to children weighing 
9–11·9 kg, one tablet to those weighing 12–19·9 kg, one 
and a half tablets to those weighing 20–27·9 kg, and two 
tablets to those weighing 28–35·5 kg. Clindamycin 
(Pﬁ zer SA/NV Brussels, Belgium) granules were 
suspended in a 75 mg/5 mL solution (in sucrose, ethyl 
parahydroxybenzoate, poloxamer, and artiﬁ cial cherry 
oil), which was administered orally twice a day for at least 
5 days at a dosage of 10 mg/kg.
All ASAQ and AL treatments were administered on 
site, under the direct supervision of study nurses. For 
logistical reasons, in DR Congo, children assigned to the 
QnC group were admitted to hospital for the ﬁ rst 3 days 
of the trial. On the fourth day, the ﬁ rst two doses were 
given under supervision, and the third, evening dose was 
given at home by the parent or guardian. After the drug 
was administered on site, children were kept at the clinic 
for 60 min. A full dose was repeated if vomiting occurred 
within 30 min of administration, and a half dose was 
administered if vomiting occurred between 30 and 
60 min. In case of persistent vomiting, the patient was 
withdrawn from the study and referred to the health 
facility for parenteral treatment.
Microscopy examination involved collecting thick and 
thin blood ﬁ lms at each visit and staining with 
10% Giemsa within 10 min. Parasites were counted over 
200 white blood cells, and density per μL estimated 
assuming 8000 white blood cells per μL. Each slide 
was read independently by two microscopists; a third 
reading was done in case of discrepancies between the 
ﬁ rst two readings. The Institute of Tropical Medicine in 
Antwerp was responsible for microscopy external quality 
control and two laboratory-speciﬁ c monitoring visits 
were done at both sites by experts from the malaria unit. 
Haemoglobin was measured at days 0, 14, and 28, by use 
of a portable spectrophotometer (Hemocontrol, EKF 
Diagnostics, Barleben, Germany). At each visit, dried 
blood spots were obtained on ﬁ lter paper (Whatman 
3 MM, Maidstone, UK) and air-dried before storage. 
DNA was extracted from dried blood spots according to 
the manufacturer’s instructions (QIAamp DNA Mini Kit, 
Hilden, Germany). To distinguish between a new 
infection and a recrudescence, we did PCR genotyping of 
the polymorphic regions of the gene encoding merozoite 
surface protein-1 (MSP1), the gene encoding merozoite 
surface protein-2 (MSP2), and glutamate-rich protein 
(GLURP), as described previously.13,14 Brieﬂ y, we 
compared the genetic signatures of the samples at day 0 
(D0) and day X (DX, at treatment failure). If at least one 
identical allele was found in these paired samples at each 
of the three loci, the failure was classiﬁ ed as recrudescent. 
When the ampliﬁ cation reaction for one locus proved to 
be negative for either one or both of the paired samples, 
the outcome was classed as indeterminate. To assess 
genotyping-adjusted outcomes, recurrent parasitaemia 
due to new infections was considered as adequate clinical 
and parasitological response (ACPR).
Outcome
The primary outcome was the proportion of children 
with ACPR after PCR adjustment at day 28 and measured 
in the per-protocol population. The ACPR was deﬁ ned as 
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the absence of parasitaemia at the end of the study 
follow-up period (day 28), regardless of tympanic 
temperature, without having previously met any of the 
criteria for early and late treatment failure.15 In the PCR-
adjusted analyses, children with recurrent infection were 
considered ACPR if this was classiﬁ ed as a new infection. 
Primary outcome was assessed in children who 
completed 28 days of follow-up without having recurrent 
malaria and those who experienced recurrent malaria 
but in whom PCR genotyping revealed a new infection 
(ie, initial parasites had been successfully cleared before 
the onset of a new episode), with children who had 
indeterminate PCR genotyping results being excluded 
from the data analyses. 
Secondary eﬃ  cacy outcomes were assessed in the per-
protocol population. This population included children 
who had a known eﬃ  cacy endpoint, without any criteria 
of protocol violation. They included fever clearance time 
(FCT), deﬁ ned as the time, in days, from randomisation 
to the ﬁ rst two consecutive measurements of tympanic 
temperature lower than 38·0°C on diﬀ erent days; 
haemoglobin changes between days 0, 14, and 28; asexual 
parasite clearance time deﬁ ned as the time, in days, from 
randomisation to two consecutive negative blood slides 
(obtained on diﬀ erent days). 
Safety endpoints were deﬁ ned as adverse events in 
children who had received at least one dose of the study 
medication. An adverse event was deﬁ ned as any 
untoward medical occurrence, regardless of its relation to 
the study medication, in accordance with the International 
Conference of Harmonisation guidelines (ICH). 
Investigators used clinical judgment to assess causality, 
and the association was deﬁ ned as deﬁ nitely unrelated, 
unlikely to be related, possibly related, probably related, 
and deﬁ nitely related. Only adverse events that were 
assessed as at least possibly related to the study drug were 
considered. These events were grouped according to the 
WHO adverse-reaction terminology (WHO-ART).
Figure 1: Trial proﬁ le for 28 days of follow-up after rescue treatment in QUINACT study participants at the Lisungi Health Centre (DR Congo) and the Kazo 
Health Centre (Uganda), 2012–14
699 children with clinical treatment 
failure assessed for eligibility
         290 in DR Congo 
         409 in Uganda 128 excluded 
109 lack of second informed consent  
1 decision of the investigator for safety reasons 
16 danger signs or severe malaria   
2 unsuccessful blood collection 
571 randomised
242 DR Congo 
329 Uganda 
 
240 assigned to ﬁrst-line ACT retreatment 
95 DR Congo, ASAQ
145 Uganda, AL
233 assigned to alternative ACT 
107 DR Congo, AL
126 Uganda, ASAQ
98 assigned to quinine + clindamycin 
40 DR Congo 
58 Uganda 
17 did not complete the study 
2 persistent vomiting 
10 lost to follow-up 
5 withdrawal of consent 
14 did not complete the study 
1 persistent vomiting 
10 lost to follow-up 
2 withdrawal of consent 
1 prohibited drug 
9 did not complete the study             
2 persistent vomiting 
6 lost to follow-up 
1 withdrawal of consent 
223 completed the study with unadjusted 
outcome
219 completed the study with unadjusted 
outcome
89 completed the study with unadjusted 
outcome
86 PCR-adjusted outcome
5 did not complete the treatment3 did not complete the treatment4 did not complete the treatment
93 modiﬁed intention-to-treat population230 modiﬁed intention-to-treat population236 modiﬁed intention-to-treat population
3 excluded for non-determinant 
PCR results 
206 PCR-adjusted outcome208 PCR-adjusted outcome
15 excluded for non-determinant 
PCR results 
13 excluded for non-determinant
PCR results 
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Statistical analysis
We hypothesised that all three treatment groups would 
have similar eﬃ  cacy and would be superior to 90%. The 
PCR-adjusted eﬃ  cacy in any treatment group was 
assumed to be 95%. Thus, the hypothesis was accepted 
if the two-sided 95% CI (Wilson’s test) fell entirely 
above 90%. We therefore needed a sample size of 
248 children (124 per site) to show with 80% power that 
the eﬃ  cacy of re-treatment with the same ACT was at 
least 90%. Treatment with QnC was intended as the 
benchmark with half of participants, given that its 
administration is more demanding, particularly in the 
context of directly observed treatment (administered 
three times a day for 7 days). Assuming 15% of children 
would be unable to be assessed, the required sample 
size was 714 (357 per site).
Using DataFax (Clinical DataFax Systems Inc, ON, 
Canada), data recorded on paper case report forms (CRFs) 
were sent weekly from both sites to a centralised database 
located at the Infectious Diseases Institute, University of 
Makerere, Uganda. Most of the data analysis was done 
with Stata version 11 (Stata Corp, Lakeway, College 
Station, TX, USA). We used descriptive statistics to 
summarise the baseline characteristics. We applied 
haemoglobin concentration of 100 g/L as a cutoﬀ  for 
anaemia as in previous studies.16 The eﬃ  cacy analysis was 
done according to both a per-protocol and a modiﬁ ed 
intention-to-treat approach. In the modiﬁ ed intention-to-
treat approach, children excluded after enrolment were 
censored at the time of their ﬁ nal examination. We did 
some post-hoc analyses of Nelson-Aalen cumulative 
hazard estimates to generate the curves for risk of PCR-
adjusted and PCR-unadjusted treatment failure. We 
compared survival curves by a log-rank test. Children who 
completed the treatment course were included in a 
sensitivity analysis with PCR-unadjusted ACPR at day 28 
in the modiﬁ ed intention-to-treat population, considering 
the children missing the treatment outcome as ACPR or 
treatment failure.
To assess the PCR-adjusted outcomes, recurrent 
parasitaemia caused by new infections was considered to 
be ACPR. Safety was analysed in all patients treated, 
which included all children who were randomly assigned 
to treatment who received at least one dose of study 
medication. We compared the percentage of children 
who had each adverse event between treatment groups. 
A p value of less than 0·05 was considered signiﬁ cant. 
Data were pooled as re-treatment (same ACT vs 
alternative ACT and same ACT vs QnC) or by regimen 
(AL vs ASAQ and AL vs QnC; see appendix). The asexual 
parasite clearance time of 154 children was closely 
monitored every 6 h in both sites, according to the 
protocol amendment. We analysed the data using the 
parasite clearance estimator (PCE),17 which estimated the 
parasite-clearance half-life. The trial protocol was 
amended to include estimating parasite clearance half-
life every 6 h for evidence of parasitaemia following 
recommendations from the Worldwide Antimalarial 
Resistance Network (WWARN).
The study is registered in ClinTrials.gov, NCT01374581, 
and the Pan African Clinical Trials Registry, 
PACTR201203000351114. External monitoring for 
purposes of guaranteeing data quality and good clinical 
practice (GCP) compliance was done by the Amsterdam 
Institute for Global Health and Development.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Re-treatment 
ACT (n=240)
Alternative
ACT (n=233)
QnC
(n=98)
DR Congo
(n=242)
Uganda
(n=329)
Mean age, months (SD) 34·4 (12·6) 35·5 (13·3) 36·0 (13·3) 37·4 (13·1) 33·4 (12·7)
Male sex (%) 131 (55%) 115 (49%) 51 (52%) 129 (53%) 168 (51%)
Median weight, kg (IQR) 12·5 (11–14) 12·5 (11–14) 12·5 (11–14) 13·0 (11–14·6) 12·0 (10·5–14)
Mean height, cm (SD) 87·3 (10·1) 88·8 (11·1) 89·0 (11·0) 91·9 (10·4) 85·5 (10·2)
Mean tympanic temperature,°C (SD) 38·0 (1·2) 37·9 (1·1) 38·0 (1·2) 38·1 (1·0) 37·8 (1·2)
Patients with fever, ≥38°C (%) 105 (44%) 99 (43%) 42 (43%) 132 (55%) 114 (35%)
Mean haemoglobin, g/L (SD) 102 (15) 104 (17) 103 (17) 103 (16) 103 (16)
Patients with anaemia (%) 82 (34%) 87 (37%) 35 (36%) 82 (34%) 122 (37%)
Geometric mean for asexual parasites per μl (95% CI) 26 776 
(21 607–33 182)
26 976 
(21 509–33 840)
27 380 
(19 357–38 729)
27 520 
(22 590–33 526)
26 561 
(21 782–32 387)
Patients with  parasitaemia ≥2000 asexual parasites 
per μL (%)
216 (90%) 212 (91%) 88 (90%) 222 (92%) 294 (89%)
Patients sleeping under mosquito bednets the previous 
night (%)
123 (51%) 130 (56%) 55 (56%) 135 (56%) 173 (53%)
Patients carrying gametocytes (%) 4 (2%) 4 (2%) 1 (1%) 1 (<1%) 8 (2%)
 Table 1: Demographic and baseline clinical characteristics of Quinact study participants at the Lisungi Health Center (DR Congo) and the Kazo Health 
Center (Uganda), 2012–14
See Online for appendix
For WWARN see http://www.
wwarn.org/partnerships/study-
groups/parasite-clearance-study-
group
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Results
From May 22, 2012 (the DR Congo site started on 
Aug 23, 2012), to Jan 31, 2014, 699 children were assessed 
for eligibility after having a recurrent infection with the 
ﬁ rst-line ACT treatment (ASAQ in DR Congo and AL in 
Uganda; ﬁ gure 1). Of these children, 571 fulﬁ lled the 
recruitment criteria. 516 of 571 eligible patients (90%) had 
parasitaemia of greater than 2000 asexual parasites per μL 
at recruitment (table 1). 240 children were randomly 
assigned to receive the re-treatment ACT (95 ASAQ in DR 
Congo and 145 AL in Uganda), 233 to the alternative ACT 
(107 AL in DR Congo and 126 ASAQ in Uganda), and 98 to 
QnC (40 in DR Congo and 58 in Uganda). Treatment 
outcomes were available for 223 (93%) children in the re-
treatment ACT, for 219 (94%) in the alternative ACT, and 
for 89 (91%) in the QnC groups (ﬁ gure 1). The most 
common reasons for not completing the follow-up were 
persistent vomiting, inattendence at follow-up, and 
withdrawal of informed consent. Baseline characteristics 
were similar across the three treatment groups (table 1). 
The proportions of children who were excluded from the 
per-protocol population were similar in the three treatment 
groups, and their baseline characteristics did not diﬀ er 
from those included in the study. For the assessment of the 
primary outcome, 15 children assigned to the same ACT, 
13 children in the alternative ACT group, and three from 
the QnC group were excluded because of indeterminate 
PCR genotyping results (ﬁ gure 1).
After PCR adjustment, ACPR assessed at day 28 was 
reached in 190 of 208 patients (91·4%; 95% CI 87·5–95·2) 
for the re-treatment ACT group, in 188 of 206 patients 
(91·3%; 87·4–95·1) for the alternative ACT group, and 
77 of 86 patients (89·5%; 83·0–96·0) for the QnC group 
(table 2). The diﬀ erence in eﬃ  cacy between the re-
treatment ACT and the alternative ACT groups was 0·08% 
(95% CI –5·5 to 5·7), 1·81% (–4·9 to 10·6) between the 
re-treatment ACT and the QnC groups, and 1·73% 
(–5·0 to 10·6) between the alternative ACT and the QnC 
groups. PCR-unadjusted and PCR-adjusted ACPR values 
were similar in both study sites after stratiﬁ cation (table 2, 
appendix). The rates of recrudescence in the three 
treatment groups were similar (log-rank test: χ²=0·22, 
p=0·894; ﬁ gure 2). Within the per-protocol population, 88 
children (40 re-treatment ACT, 35 alternative ACT, and 
13 QnC treatment groups) still had similar P falciparum 
strains as at the initial enrolment in the pre-trial phase. 
After rescue treatment, the proportion of persistent 
recrudescence was distributed in the three groups as 
follows: ﬁ ve (13%) of 40 children in the re-treatment ACT 
group, four (11%) of 35 children in the alternate ACT 
group, and four (31%) of 13 in the QnC treatment group.
The unadjusted ACPR in the per-protocol population 
was 135 of 223 patients (60·5%; 95% CI 54·1–67·0) for 
the re-treatment ACT, 123 of 219 patients (56·2%; 
49·6–62·8) for the alternative ACT, and 63 of 89 patients 
(70·8%; 61·3–80·3) for the QnC group (appendix). No 
treatment failure occurred before day 14. The sensitivity 
analysis in the modiﬁ ed intention-to-treat population 
showed that the proportion of patients with PCR-
unadjusted ACPR was 135 of 236 patients (57·2%; 
95% CI 50·8–63·5) when the treatment given to children 
with an unknown eﬃ  cacy endpoint was considered as a 
treatment failure and was 145 of 236 (61·4%; 55·2–67·7) 
when treatment was considered as successful in the re-
treatment ACT group. In the group given an alternative 
ACT, the ACPR ranged from 123 of 230 patients (53·5; 
47·0–59·9) to 132 of 230 (57·4%; 50·9–63·8), with ACPR 
values ranging from 63 of 93 patients (67·7%; 58·2–77·3) 
to 66 of 93 (71·0%; 61·7–80·3) in the group treated with 
QnC. Malaria recurrent infection tended to occur later in 
Re-treatment ACT (%) Alternative ACT (%) QnC (%)
Overall
New infections 56/73 (75%) 65/83 (78%) 14/23 (61%)
Recrudescence 18/73 (25%) 18/83 (22%) 9/23 (39%)
Indeterminate n 15 13 3
ACPR n/N (%, 95% CI) 190/208
(91%, 87·5–95·2)
188/206
(91%, 87·4–95·1)
77/86
(90%, 83·0–96·0)
DRC
New infections 20/26 (77%) 31/39 (80%) 6/10 (60%)
Recrudescence 6/26 (23%) 8/39 (21%) 4/10 (40%)
Indeterminate n 2 4 2
ACPR n/N (%; 95% CI) 80/86
(93%, 87·6–98·5)
89/97
(92%, 86·2–97·3)
31/35
(89%, 77·8–99·3)
Uganda
New infections 35/47 (75%) 34/44 (77%) 8/13 (62%) 
Recrudescence 12/47 (26%) 10/44 (23%) 5/13 (39%)
Indeterminate n 13 9 1
ACPR n/N (%, 95% CI) 110/122
(90%, 84·4–95·5)
99/109
(91%, 85·4–96·3)
46/51
(90%, 81·9–98·5)
Data are n/N (%) unless otherwise indicated
Table 2: PCR-adjusted treatment outcome of the rescue treatment by day 28 (per-protocol population) 
for QUINACT study participants at the Lisungi Health Center (DR Congo) and the Kazo Health Center 
(Uganda), 2012–14 
Figure 2: Nelson-Aalen PCR-adjusted estimates for rates of recurrent malaria 
infection in the modiﬁ ed intention-to-treat population in the re-treatment 
ACT group, Alternative ACT group, and quinine and clindamycin groups.
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the patients assigned to QnC, compared with the other 
groups (log-rank test χ²=5·73, p=0·056; appendix). 
Fever resolution was less rapid in children assigned to 
QnC treatment than in children assigned to either ACT 
treatment group (appendix). The proportion of children 
with parasitaemia on days 1, 2, and 3 was higher in the 
QnC group than in either of the ACT treatment groups. 
On day 7, all children had negative blood smears. The 
parasite clearance trend can be seen in the appendix. 
Children given QnC had a longer half-life parasite 
clearance (mean 6·2 h; SD 2·1), than did those treated 
with AL (2·7 h; 1·0) or ASAQ (2·4 h; 1·3; both 
p<0·0001), although this parasite clearance was similar 
between the ACT groups (p=0·40). The observation was 
similar when stratiﬁ ed by site, although the QnC group 
was under-represented.
On day 28, the mean haemoglobin increased by 12 g/L 
(SD 17) in the re-treatment ACT, 11 g/L (18) in the 
alternative ACT, and 16 g/L (14) in the QnC groups 
(appendix). When pooled by regimen, the mean increase 
was 11 g/L (18) for AL and 12 g/L (18) for ASAQ 
(appendix). None of the diﬀ erences between mean 
increases were signiﬁ cant.
Pooling data by regimen, 252 children were assigned to 
AL and 221 were assigned to ASAQ. The baselines for the 
two groups were similar (appendix). The PCR-unadjusted 
ACPR value for AL was 133 of 236 (56·4; 95% CI 
50·0–62·7), and 125 of 206 (60·7%; 53·9–67·4) for ASAQ 
(appendix). The PCR-adjusted ACPR was similar for both 
AL and ASAQ treatment groups (199 of 219; 90·9%; 
87·0–94·7 vs 179 of 195; 91·8%; 87·9–95·7) with a log-rank 
test (χ²) value of 0·20 ( p=0·903; appendix). The percentage 
of children with fever on days 1, 2, and 3 was lower in the 
ASAQ group than the AL and QnC treatment groups 
(appendix). The PCR-unadjusted ACPR was similar to the 
unadjusted values (appendix). The site-speciﬁ c cumulative 
hazard estimates are presented in the appendix.
Overall, 235 adverse events were observed (table 3). The 
most common events (>5%) reported in the re-treatment 
ACT group were anorexia, asthenia, coughing, abnormal 
behaviour, and diarrhoea. Anorexia was the most 
frequently reported adverse event in the alternative ACT 
group, although anorexia, abnormal behaviour, asthenia, 
and pruritus were the most commonly reported after 
treatment with QnC. None of the adverse events were 
considered serious. The group assigned to alternative ACT 
had fewer drug-related adverse events than the re-
treatment ACT group (p<0.0001) and the QnC treatment 
group (p<0·0001).
66 adverse events were observed in the AL group, and 
121 in the ASAQ group. The most commonly reported 
adverse events were abdominal pain, abnormal 
behaviour, anorexia, asthenia, and coughing in the ASAQ 
group, and anorexia and diarrhoea were the most 
commonly reported in the AL group (appendix). One 
case of either hypoglycaemia or convulsions occurred in 
the QnC group, and one case of abnormal urine (verbatim 
“dark urine”) was reported in the ASAQ group and in the 
AL group. Of all adverse events reported, ten (6%) were 
graded as severe. AL was better tolerated, compared with 
QnC (p=0·0005) and ASAQ (p<0·0001).
Discussion
The PCR-adjusted eﬃ  cacy of the three diﬀ erent rescue 
treatments tested was similar. Treating a patient with a 
recurrent P falciparum infection with the same treatment 
used for the primary episode had similar eﬃ  cacy to 
other options, and this should be considered as a 
possible approach for rescue treatment. However, its 
eﬀ ect on the selection of P falciparum resistant strains 
should be monitored.
The PCR-unadjusted eﬃ  cacy of QnC tended to be 
higher than the eﬃ  cacy of the other two groups. This 
observation is probably related to the length of 
treatment—7 days for QnC compared with 3 days for 
the other two treatments. However, in both geographical 
sites, the proportion of recrudescence seemed to be 
higher in the QnC group, though the sample size is too 
Re-treatment 
ACT n=240 (%)
Alternative 
ACT n=233 (%)
QnC
n=98 (%)
Abdominal pain 8 (3%) 10 (4%) 1 (1%)
Abnormal behaviour 13 (5%) 3 (1%) 6 (6%)
Allergic reaction 1 (<1%) 0 (0%) 0 (0%)
Anaemia 0 0 (0%) 1 (1%)
Anorexia 31 (13%) 13 (6%) 12 (12%)
Asthenia 20 (8%) 2 (1%) 6 (6%)
Bradycardia 1 (<1%) 0 (0%) 0 (0%)
Bronchitis 1 (<1%) 0 (0%) 0 (0%)
Convulsions 0 (0%) 0 (0%) 1 (1%)
Coughing 16 (7%) 6 (3%) 0 (0%)
Diarrhoea 12 (5%) 9 (4%) 2 (2%)
Dizziness 0 (0%) 1 (<1%) 1 (1%)
Headache 0 (0%) 0 (0%) 1 (1%)
Hypoglycaemia 0 (0%) 0(0%) 1 (1%)
Jaundice 1 (<1%) 1 (<1%) 0 (0%)
Musculoskeletal pain 1 (<1%) 0 (0%) 0 (0%)
Nausea 5 (2%) 3 (1%) 4 (4%)
Periorbital oedema 0 (0%) 1 (<1%) 0 (0%)
Pruritus 9 (4%) 1 (<1%) 5 (5%)
Rales 1 (<1%) 0 (0%) 0 (0%)
Rash 2 (1%) 1 (<1%) 1 (1%)
Splenomegaly 0 (0%) 1 (<1%) 0 (0%)
Tachycardia 0 (0%) 1 (<1%) 2 (2%)
Tinnitus 0 (0%) 0 (0%) 2 (2%)
Urine abnormal 1 (<1%) 1 (<1%)) 0 (0%)
Vomiting 8 (3%) 2 (1%) 2 (2%)
Total 131 56 48
Table 3: Summary of adverse events occurring up to day 28 in patients 
having received at least one dose (n=571) for QUINACT study 
participants at the Lisungi Health Center (DRC) and the Kazo Health 
Center (Uganda), 2012–14 
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small to estimate the actual eﬃ  cacy of QnC by site. In 
previous trials in Uganda, the proportion of PCR-
adjusted treatment failure after treatment with quinine 
was 11·4% in Tororo11 and 69% in Kampala.5 It is worth 
noting that the study by Achan and colleagues5 showed 
only an estimation of quinine eﬀ ectiveness as the 
treatment was not directly observed and the study 
reﬂ ects poor treatment adherence. There is a paucity of 
data on the eﬃ  cacy of quinine as a treatment for 
uncomplicated malaria in DR Congo.
Despite good PCR-adjusted eﬃ  cacy and tendency for 
a long post-treatment prophylactic period, QnC might 
not be suitable for rescue treatment for several reasons, 
including the long duration of treatment and poor 
tolerance, which can aﬀ ect adherence, thereby resulting 
in poor eﬀ ectiveness.5,18 Additionally, the availability of 
clindamycin is restricted in most sub-Saharan settings, 
particularly for children.19,20 Clindamycin can also 
induce antibiotic-associated diarrhoea and its use on a 
large scale in malaria treatment (in combination with 
quinine) could contribute to the spread of bacterial 
resistance. The paediatric formulation (granules for oral 
suspension in sucrose, ethyl parahydroxybenzoate, 
poloxamer, and artiﬁ cial cherry oil) is unstable and 
requires storage at 25°C or less, which poses a challenge 
in many endemic areas.
In a study done in Uganda, Yeka and colleagues11 
reported that alternative ACT is a better rescue treatment 
than quinine. However, the option of re-treating with the 
same ACT used for the primary episode was not 
considered. The risk of recurrent infections was much 
higher in Tororo, where the study was done, than that 
observed in Kazo, a diﬀ erence related to the much higher 
intensity of transmission.
The proportion of children with detectable para-
sitaemia on days 1, 2, and 3 was higher in the QnC 
group than in the ACT groups. The added value of 
clindamycin to the reduction in asexual parasite 
clearance time with quinine is uncertain.19,20 Two 
children (1%) of 135 in the AL group in Uganda had 
microscopically detectable parasitaemia on day 3 after 
re-treatment. This outcome is not common with ACT.2 
In DR Congo, all children randomly assigned to the 
ACT groups cleared parasites by day 3. Close 
monitoring (every 6 h) showed a similar parasite 
clearance half-life for ASAQ and AL, but much longer 
for QnC. The number of children involved in this 
analysis was small as this study procedure was added as 
a protocol amendment during the study. It is important 
to provide more data on the parasite clearance 
estimations, since these data would provide relevant 
information for the surveillance of artemisinin 
resistance.21 It is worth mentioning that with almost 
1000 samples obtained in the DR Congo site, we 
contributed to the publication by the Karma consortium, 
in which it is indicated that K13 resistance is most 
probably not present in DR Congo.22
The group re-treated with the same ACT had more 
adverse events because of the higher proportion of 
adverse events in the DR Congo site. In principle, re-
treatment with the same ACT does not reduce the safety 
proﬁ le.23,4 The adverse events observed in the group 
treated with QnC are likely to be caused by quinine, 
given that clindamycin is reported to be well tolerated.19 
The group assigned to AL treatment had fewer adverse 
events than the groups given ASAQ or QnC. In general, 
both AL and ASAQ are well tolerated.4,24–26
This study has some limitations. The sample size 
calculation was based on the assumption of a 95% eﬃ  cacy 
for the three rescue treatments, which required the lower 
limit of the 95% CI to be above 90%. However, the point 
estimate of the PCR-adjusted eﬃ  cacy of all treatments 
was lower than expected. Therefore, both ACTs had a 
similar 95% CI with a lower limit of 87·5% for the same 
ACT and 87·4% for the alternative ACT groups. The 
availability of resistance marker results could provide 
additional arguments for or against re-treatment with the 
same ACT although this information could be acquired 
in a classic randomised trial design. Because of potential 
residual submicroscopic parasitaemia that could persist 
after ACT treatment, the conventional PCR-adjustment 
used in this study might have some limitations in the 
classiﬁ cation of new infections and recrudescence, which 
might be avoided by the use of quantitative PCR.27
Few trials have investigated the rescue treatment of 
uncomplicated malaria. This study provides evidence on 
the 28-day eﬃ  cacy of re-treatment with the same ACT, a 
relatively common practice. The study also contributes to 
the scarce information on the eﬃ  cacy of QnC. The high 
proportion of new infections is an indicator of the high 
malaria transmission in the study areas. The failure to 
clear recrudescent parasites seemed to be similar in both 
ACT groups, but higher in the QnC group. The number 
of patients in this subset might not allow making a 
conclusive statement in terms of signiﬁ cance. A study 
including a population aged more than 5 years and a 
longer follow-up period would provide more evidence for 
the generalisability of these results. The 42 days of passive 
follow-up in pre-trial phase and a shorter 28 days of active 
follow-up in the study phase was necessary to protect the 
quality of data and avoid the overcrowding of study sites.
Conclusion
If we consider the poor eﬀ ectiveness and tolerability of 
quinine, the reduced availability of the paediatric 
formulation of clindamycin, and the availability of only 
one ﬁ rst-line ACT at the community level in many settings, 
we conclude that a rescue treatment with the same ACT in 
correct doses as recommended could be an alternative 
option to quinine or the not always available alternative 
ACT. More evidence is needed before assessing the 
generalisability of this statement and caution is paramount 
when re-treating with the ﬁ rst-line ACT in areas where 
resistance to the partner drug has been conﬁ rmed.
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